📰 Mark Joinnides News
Page 2 - Mark Joinnides News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Joinnides. Real-time updates on events, politics, business and more.
August 29, 2023
CAPE CANAVERAL, Fla., Aug. 29, 2023 -- Vaxxinity, Inc. ; class=js-l-obf link link--blue
August 10, 2023
Phase 2a data published in The Lancet’s eBioMedicinesupports further development of UB-311
August 9, 2023
CAPE CANAVERAL, Fla., Aug. 09, 2023 -- Vaxxinity, Inc. ; class=js-l-obf link link--blue
July 27, 2023
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...
July 17, 2023
Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s...
June 22, 2023
UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further cl...
May 9, 2023
CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
May 9, 2023
CAPE CANAVERAL, Fla., May 09, 2023 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first... | May 9, 2023
March 28, 2023
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine... | March 28, 2023
March 27, 2023
CAPE CANAVERAL, Fla., March 27, 2023 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth... | March 27, 2023